MDS 2023 | Real-world validation of the value of the IPSS-M for prognostication in patients with MDS

Matteo Della Porta, MD, Humanitas Research Hospital, Milan, Italy, discusses the recently published real-world validation of the Molecular International Prognostic Scoring System (IPSS-M) for myelodysplastic syndromes (MDS). Prof. Della Porta provides a brief overview of the development of the IPSS-M and explains that the validation study confirmed the increased prognostic value of the IPSS-M compared with the Revised IPSS (IPSS-R). Prof. Della Porta further highlights the value of the IPSS-M for predicting responses to specific treatments, determining the probability of relapse in patients who receive allogeneic stem cell transplantation (alloSCT), and identifying candidates for preemptive therapy before or after alloSCT. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.